Ranbaxy to launch Daiichi Sankyo's antihypertensive drug in India
Ranbaxy Laboratories Limited and Daiichi Sankyo Company Limited announced on March 31, 2009 that Ranbaxy will launch Olvance (Olmesartan Medoxomil, antihypertensive), which was originally discovered by Daiichi Sankyo. This follows a licensing agreement between the two companies authorising Ranbaxy to promote and market the drug in India.
Commenting on the occasion, Malvinder Mohan Singh, Chairman, CEO and Managing Director, Ranbaxy, said, “The launch of Olvance is a historic moment in the collaboration between Ranbaxy and Daiichi Sankyo. This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”
Remarking on the development,Takashi Shoda, President and CEO of Daiichi Sankyo, said, “We are delighted with the introduction of Olvance in the Indian market by Ranbaxy, signifying our serious commitment to India. Olmesartan Medoxomil is a superior antihypertensive medicine that will offer an excellent therapy option to the doctors and patients in India. This marks our intent to scale up our innovative product introductions, in India, through Ranbaxy.”
Source: Ranbaxy